- In September 2024, Novo Nordisk has announced a new partnership to establish human insulin production in South Africa, strengthening its commitment to diabetes care in Africa. Currently reaching 500,000 people in Sub-Saharan Africa, this initiative aims to expand insulin access, with a goal of supplying 4.1 million people with type 1 and type 2 diabetes across the continent by 2026
- In August, Eli Lilly announced positive results from the SURMOUNT-1 study, showing that weekly tirzepatide (Zepbound/Mounjaro) reduced the risk of type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight. The 15 mg dose led to a 22.9% average weight loss over 176 weeks, demonstrating sustained efficacy
- In December 2022, Sanofi expanded its collaboration with Innate Pharma, focusing on natural killer (NK) cell engagers in oncology. Sanofi licensed the B7H3-targeting NK cell engager program from Innate's ANKET platform, with the option to add two more targets. This partnership aims to develop new cancer therapies, including treatments for solid tumors, enhancing Sanofi's immuno-oncology pipeline. The collaboration is expected to provide innovative cancer treatment options with a strong safety profile, benefiting patients by offering potential therapies for multiple cancer types. Sanofi will handle further development, manufacturing, and commercialization responsibilities
- In December 2024, Lupin Acquired Huminsulin from Lilly to Enhance Diabetes Portfolio. It was performed in the aim to expand diabetes portfolio and provide high-quality, affordable health care to our patients
